The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation

Laboratory Investigation

Volumn 93, Issue 6, 2013, Pages 711-719

  Simons, Andrean L ^a,b,c   Lu, Ping ^b   Gibson Corley, Katherine N ^a   Robinson, Robert A ^a,c   Meyerholz, David K ^a   Colgan, John D ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

EGFR; Gon4l; Justy; myoepithelial; salivary gland cancer

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYTOKERATIN AE1; CYTOKERATIN AE3; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN P63; PROTEIN S 100; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL; BASAL CELL CARCINOMA; CANCER MODEL; CELL DIFFERENTIATION; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MITOSIS; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; PAROTID GLAND; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SALIVARY GLAND CANCER; SIGNAL TRANSDUCTION; SPINDLE CELL; SUBLINGUAL GLAND; WILD TYPE;

EID: 84878525918     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.62     Document Type: Article

References (46)

1. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177-184.
2. Witt RL. Major salivary gland cancer. Surg Oncol Clin N Am 2004;13: 113-127.
3. Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol 2008;35:309-319.
4. Declercq J, Van Dyck F, Braem CV, et al. Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res 2005;65:4544-4553.
5. Diegel CR, Cho KR, El-Naggar AK, et al. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res 2010;70:9143-9152.
6. Tsukamoto AS, Grosschedl R, Guzman RC, et al. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988; 55:619-625.
7. Lucchini F, Sacco MG, Hu N, et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett 1992;64:203-209.
8. Taneja P, Frazier DP, Kendig RD, et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 2009;9:423-440.
9. Lu P, Hankel IL, Knisz J, et al. The Justy mutation identifies Gon4-like as a gene that is essential for B lymphopoiesis. J Exp Med 2010;207: 1359-1367.
10. Friedman L, Santa Anna-Arriola S, Hodgkin J, et al. Gon-4, a cell lineage regulator required for gonadogenesis in Caenorhabditis elegans. Dev Biol 2000;228:350-362.
11. Liu Y, Du L, Osato M, et al. The zebrafish udu gene encodes a novel nuclear factor and is essential for primitive erythroid cell development. Blood 2007;110:99-106.
12. Hrabe de Angelis MH, Flaswinkel H, Fuchs H, et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet 2000;25:444-447.
13. Augustin M, Sedlmeier R, Peters T, et al. Efficient and fast targeted production of murine models based on ENU mutagenesis. Mamm Genome 2005;16:405-413.
14. Lu P, Hankel IL, Hostager BS, et al. The developmental regulator protein Gon4l associates with protein YY1, co-repressor Sin3a, and histone deacetylase 1 and mediates transcriptional repression. J Biol Chem 2011;286:18311-18319.
15. Kitsiou-Tzeli S, Kolialexi A, Fryssira H, et al. Detection of 22q11.2 deletion among 139 patients with Di George/Velocardiofacial syndrome features. In Vivo 2004;18:603-608.
16. Bansal N, Kadamb R, Mittal S, et al. Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress. PLoS One 2011;6: e26156.
17. Liao M, Zhang Y, Dufau ML. Protein kinase C alpha-induced derepression of the human luteinizing hormone receptor gene transcription through ERK-mediated release of HDAC1/Sin3A repressor complex from Sp1 sites. Mol Endocrinol 2008;22:1449-1463.
18. Sheeba CJ, Palmeirim I, Andrade RP. Chick Hairy1 protein interacts with Sap18, a component of the Sin3/HDAC transcriptional repressor complex. BMC Dev Biol 2007;7:83.
19. Clem BF, Clark BJ. Association of the mSin3A-histone deacetylase 1/2 corepressor complex with the mouse steroidogenic acute regulatory protein gene. Mol Endocrinol 2006;20:100-113.
20. Peinado H, Ballestar E, Esteller M, et al. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004;24:306-319.
21. Kim DW, Lassar AB. Smad-dependent recruitment of a histone deacetylase/Sin3A complex modulates the bone morphogenetic protein-dependent transcriptional repressor activity of Nkx3.2. Mol Cell Biol 2003;23:8704-8717.
22. Hahn JN, Falck VG, Jirik FR. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J Clin Invest 2011;121:4030-4042.
23. Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006;441: 1015-1019.
24. Law LW, Dunn TB, Boyle PJ. Neoplasms in the C3H strain and in F1 hybrid mice of two crosses following introduction of extracts and filtrates of leukemic tissues. J Natl Cancer Inst 1955;16:495-539.
25. Sundberg JP, Hanson CA, Roop DR, et al. Myoepitheliomas in inbred laboratory mice. Vet Pathol 1991;28:313-323.
26. Batsakis JG, Regezi JA, Luna MA, et al. Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol Otol 1989;103:939-944.
27. Riva A, Serra GP, Proto E, et al. The myoepithelial and basal cells of ducts of human major salivary glands: a SEM study. Arch Histol Cytol 1992;55(Suppl):115-124.
28. Savera AT, Sloman A, Huvos AG, et al. Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol 2000;24:761-774.
29. Clauditz TS, Reiff M, Gravert L, et al. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 2011;43: 459-464.
30. Robinson RA. Salivary Gland. Head and Neck Pathology-Atlas for Histologic and Cytologic Diagnosis, Philadelphia, 2010, pp228-232.
31. Ellis GL, Auclair P. Tumors of the Salivary Gland. AFIP Atlas of Tumor Pathology, Silver Spring, 2008, pp347-348.
32. Nagao T, Sugano I, Ishida Y, et al. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. Cancer 1998;82:439-447.
33. Zheng S, Guo Y, Mones JM. Basal cell carcinoma with myoepithelial differentiation. Am J Dermatopathol 2011;33:863-866.
34. Skalova A, Jakel KT. Myoepithelial carcinoma. In: Barnes L, Eveson JW, Reichert P, Sidransky D (eds.) World Health Organization Classification of Tumours: Pathology & Genetics of Head and Neck Tumours, Lyon, 2005, pp240.
35. Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 2012;106:719-726.
36. Ettl T, Stiegler C, Zeitler K, et al. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 2012;43:921-931.
37. Ettl T, Schwarz S, Kleinsasser N, et al. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53:567-577.
38. Monteiro LS, Bento MJ, Palmeira C, et al. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 2009;38:508-513.
39. Knox SM, Lombaert IM, Reed X, et al. Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis. Science 2010;329:1645-1647.
40. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
41. Zwick E, Hackel PO, Prenzel N, et al. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 1999;20:408-412.
42. Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
43. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356.
44. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-3584.
45. Eveson JW, Auclair P, Gnepp DR, et al. Tumours of the salivary glands: Introduction. In: Barnes L, Eveson JW, Reichert P, Sidransky D (eds.) World Health Organization Classification of Tumours: Pathology & Genetics of Head and Neck Tumours, Lyon, 2005, pp213.
46. Ungari C, Paparo F, Colangeli W, et al. Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms. Eur Rev Med Pharmacol Sci 2008;12:321-325.